Syntera Automations

About Syntera

The Syntera Origin Story

Syntera was founded with a clear purpose: to bridge the gap between scientific innovation and real-world patient impact. After years of experience in healthcare delivery and systems management, Jamie Gray identified a critical challenge — many life-saving therapies stall in development or never reach the people who need them due to high costs, complex processes, and regulatory barriers.

Syntera was created to solve this problem — as a formulation-driven licensing platform designed for speed, precision, and adaptability. By focusing on regulatory efficiency, scientific rigor, and scalable partnerships, Syntera ensures that promising therapies move forward faster and reach patients sooner.

My Founder Story

“I founded Syntera not to follow convention, but to challenge it. Too many critical treatments never make it beyond the lab, leaving patients and families without options. I believed there had to be a better way — a smarter, more accessible model that prioritizes innovation, ethical development, and meaningful collaboration.

Syntera is that model: a focused, execution-driven platform built to accelerate therapies from concept to care — with the ultimate goal of transforming lives worldwide.”

Pipeline

Syntera Biologics is advancing a next-generation pipeline of long-acting, precision-engineered therapeutics addressing high-burden, underserved conditions across oncology, CNS, and metabolic domains.

CarciLimin™

For Cancer Cachexia

Syntera Balance™ (4-API)

For Metabolic and Addiction Disorders

Cogniva-X™

For Neurodegenerative and Cognitive Disorders

Buprenorphine (Long-acting)

For Advanced Cancer Pain

HZ-Nano™

For Resistant Hypertension and Heart Failure

MetPEG

MetPEG: Weekly injectable metformin platform addressing type 2 diabetes (537M patients, human PK Q1 2026), PCOS (116M women, potential first approved therapy, $1-2B peak), and high-risk women's metabolic health including BRCA carriers (2-3M women, metabolic management with cancer risk reduction, $400-800M peak), creating a diversified multi-billion-dollar metabolic health franchise from capital-efficient 505(b)(2) pathway.

This pipeline reflects Syntera’s commitment to developing innovative, durable solutions that transform care for patients with limited treatment options.

Solutions

Transforming Healthcare Through Smarter Formulations

Global Access for Underserved Therapeutic Areas

The Problem: Diseases like cachexia, neuroinflammation, and metabolic disorders remain underserved due to lack of investment, despite high clinical need.

Our Solution: We focus on these therapeutic gaps with differentiated, multi-API injectables optimized for regional licensing—empowering partners to bring high-impact therapies to market.

Lean, Ethical Advancement Without Overbuilding

The Problem: Pharma assets are often over-engineered, over-tested, and under-licensed—leading to waste and delay.

Our Solution: Syntera advances assets using the minimal effective data strategy—PBPK simulation, bridging literature & targeted preclinical work. We add GLP studies only when they strengthen the license.

Ethical Innovation Without Unnecessary Animal Testing

The Problem: Traditional drug development relies heavily on animal testing—causing ethical concerns and delays.

Our Solution: Syntera minimizes animal use via a simulation-first model (PBPK, literature bridging, mechanistic validation). When required, we partner with GLP labs aligned to 3Rs: Replace, Reduce, Refine.

Licensing-Ready Formulations Without the Wait

The Problem: Traditional drug development timelines are too long, costly, and often stall before commercialization—especially injectables.

Our Solution: Syntera delivers assignable, partner-ready formulations with clear IP, MOA, and scalability—optimized for fast-track pathways like 505(b)(2).

How it works

Harbor Health Anchored in Care and Commitment

At Syntera, we bridge the gap between science and real-world healthcare. Our focus is on therapies that address unmet medical needs, ensuring care is not just advanced—but also accessible, ethical, and equitable.

Select for Unmet Need & Social Impact – Targeting diseases where treatments are inadequate or inaccessible.
License with Global Equity in Mind – Partnering with pharma to expand access and localize manufacturing.
Engineer Regulatory-Efficient Formulations – Building PEGylated, microsphere & nano injectables for faster approval.
Validate Strategically, Ethically & Fast – Using modern simulations & GLP-aligned labs only when data adds value

Leadership, Innovation, and Global Collaboration Driving the Future of Therapeutics

BD Management

Syed Farukh Abbas is the Business Development Manager at Syntera, where he leads global partnerships, licensing opportunities, and market entry strategies for the company’s pipeline of social therapeutics. With more than 20 years of healthcare experience, including 18 years at Pfizer, Syed has deep expertise in business development, strategic alliances, and cross-border commercialization. At Syntera, he is committed to advancing innovative, long-acting therapeutics designed for accessible, ethical, and real-world impact.

Our team is relentless in our pursuit of transformative science, strategic partnerships, and global impact — shaping the next generation of care for patients and families worldwide.

Leadership & Vision

Our leadership team brings together decades of experience across drug development, AI-powered compliance solutions, clinical practice, and healthcare systems innovation. From pioneering PEGylated therapeutics to shaping cutting-edge neuro-metabolic and oncology pipelines, our executives and advisors set the vision while driving measurable impact.

Collaborative Network

We partner globally with CROs, academic institutions, pharmaceutical innovators, and business development advisors to scale Syntera’s pipeline across multiple therapeutic areas. Our integrated approach enables us to de-risk early development, compress timelines, and maximize licensing potential in key markets worldwide.

Scientific & Regulatory Expertise

Syntera’s R&D team collaborates with leading formulation scientists, CROs, and global regulatory experts to deliver innovative solutions at speed. We specialize in:

Advanced drug delivery platforms, including PEGylation, microsphere hybrids, and BBB-targeting nanocarriers.
Strategic regulatory pathways, leveraging 505(b)(2) submissions, orphan drug designations, and innovative literature-bridging strategies.
Accelerated, cost-efficient preclinical and licensing models that meet FDA and ICH standards.

Driving the Future of Therapeutics

With a growing portfolio of high-value assets — including CarciLimin™, Syntera Balance™, HZ-Nano™, Cogniva-X™, and NeuroSlim™ — Syntera is redefining the landscape of supportive-care, metabolic, cardiovascular, and CNS-targeted therapies.